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Tumors are characterized by extracellular matrix
(ECM) remodeling and stiffening. The importance of
ECM remodeling to cancer is appreciated; the rele-
vance of stiffening is less clear. We found that breast
tumorigenesis is accompanied by collagen cross-
linking, ECM stiffening, and increased focal adhe-
sions. Induction of collagen crosslinking stiffened
the ECM, promoted focal adhesions, enhanced PI3
kinase (PI3K) activity, and induced the invasion of
an oncogene-initiated epithelium. Inhibition of integ-
rin signaling repressed the invasion of a premalignant
epithelium into a stiffened, crosslinked ECM and
forced integrin clustering promoted focal adhesions,
enhancedPI3K signaling, and induced the invasion of
a premalignant epithelium. Consistently, reduction of
lysyl oxidase-mediated collagen crosslinking pre-
ventedMMTV-Neu-induced fibrosis, decreased focal
adhesions and PI3K activity, impeded malignancy,
and lowered tumor incidence. These data show how
collagen crosslinking can modulate tissue fibrosis
and stiffness to force focal adhesions, growth factor
signaling and breast malignancy.
INTRODUCTION
The tumor stroma is characterized by extracellular matrix (ECM)
remodeling andstiffening, and tissue stiffness hasbeenexploitedto detect cancer (Butcher et al., 2009; Sinkus et al., 2000). ECM
stiffness enhances cell growth and survival and promotes migra-
tion (Lo et al., 2000), andECM rigidity disrupts tissuemorphogen-
esis by increasing cell tension (Paszek et al., 2005). Reduction of
cell tension repressed the malignant behavior of mammary
epithelial cells (MECs) and normalized the behavior of breast
cancer cells in culture (Paszeket al., 2005).WhatdrivesECMstiff-
ening in tumors and whether ECM tension could drive tumor
progression has yet to be determined.
Collagen is the most abundant ECM scaffolding protein in the
stroma and contributes significantly to the tensile strength of
tissue (Kolacna et al., 2007). Collagenmetabolism is deregulated
in cancer, where increased collagen expression, elevated depo-
sition, altered organization, and enhanced matrix metalloprotei-
nase (MMP) activity and collagen turnover have been implicated
in tumor progression (Jodele et al., 2006). MMP-mediated
collagen remodeling can create space for cells to migrate,
produce substrate cleavage fragments with independent biolog-
ical activity, modify adhesion to regulate tissue architecture, and
activate, deactivate, or alter the activity of signaling molecules
(Page-McCaw et al., 2007). Although high levels of MMPs corre-
late with poor prognosis in cancer patients (Tetu et al., 2006) and
modulation of MMP activity changes tumor phenotype (Zhang
et al., 2008), MMP inhibitors failed clinically (Coussens et al.,
2002), indicating other ECM remodeling parameters regulate
malignancy.
Type I collagen is considered a structural barrier against tumor
invasion, but paradoxically, increased expression of collagen is
associated with elevated incidence of metastasis (Ramaswamy
et al., 2003). Indeed, mammographic density, which is charac-
terized by higher collagen I, increases breast cancer risk (MartinCell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 891
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and Boyd, 2008). Importantly, collagen crosslinking accom-
panies tissue fibrosis (van der Slot et al., 2005), and fibrosis
increases risk ofmalignancy (Colpaert et al., 2003). Lysyl oxidase
(LOX), a copper-dependent amine oxidase (Kagan and Li, 2003)
that initiates the process of covalent intra- and intermolecular
crosslinking of collagen by oxidatively deaminating specific
lysine and hydroxylysine residues located in the telopeptide
domains (Yamauchi and Shiiba, 2008), is frequently elevated in
tumors (Erler et al., 2009). Active LOX stiffens tissues and can
compromise their function (Pfeiffer et al., 2005), and reduction
of LOX activity tempers tissue stiffness and prevents fibrosis
(Georges et al., 2007). Nevertheless, the relationship between
collagen crosslinking, tissue fibrosis and tension, and cancer
has yet to be assessed.
Integrins transduce cues from the ECM by assembling adhe-
sion plaque complexes that initiate biochemical signaling and
stimulate cytoskeletal remodeling to regulate cell behavior
(Miranti and Brugge, 2002). Force increases integrin expression,
activity, and focal adhesions (Paszek et al., 2005; Sawada et al.,
2006). Human breast tumors are often fibrotic and stiff, and
breast cancer cells that exhibit high tension have elevated integ-
rins and focal adhesions and increased integrin signaling (Madan
et al., 2006; Mitra and Schlaepfer, 2006). Thus, ECM stiffness
could regulate malignancy by enhancing integrin-dependent
mechanotransduction. Consistently, breast malignancy can be
inhibited by genetically ablating integrin expression (White et al.,
2004), and breast cancer cell behavior can be repressed by inhi-
bition of integrin activity or reduction of cell tension (Paszek et al.,
2005). Likewise, knockdown of the expression or inhibition of the
function of focal adhesion kinase (FAK) or p130Cas, two integrin
adhesion plaque proteins, impedes breast tumor progression
(Cabodi et al., 2006; Lahlou et al., 2007). Here, we askedwhether
collagen crosslinking could stiffen the ECM and induce fibrosis
to promote breast malignancy by altering integrins and whether
inhibition of collagen crosslinking could prevent fibrosis and
impede breast tumorigenesis by reducing integrin signaling.
RESULTS
ECM Stiffening and Collagen Crosslinking Accompany
Breast Tumor Progression
The HER2 gene is a member of the epidermal growth factor
receptor (EGFR) family that is amplified in 20%–25% of human
breast cancers. The rat equivalent of HER2 is the wild-type
Neu transgene, which, under the MMTV promoter (MMTV-
Neu), develops breast tumors with a long latency (Kim andMuller, 1999). Using the MMTV-Neu model, we studied the rela-
tionship between tissue fibrosis, stiffness, and cancer. Uncon-
fined compression and rheological testing showed an incre-
mental stiffening of the mammary gland as it transitioned from
normal to premalignant to invasive cancer (Figures 1A–1C, top)
and demonstrated that the stromal tissue adjacent to the
invading epithelium was also substantially stiffer than normal.
Total levels (Figure S1 available online) and amount of fibrillar
collagen increased markedly (Figures 1C and 1D), and second
harmonics generation (SHG) imaging revealed the progressive
linearization of the collagen adjacent to the developing epithelial
lesions (Figures 1E and 1F).
We next exploredwhether collagen crosslinking could account
for the dramatic ECM remodeling and stiffening. We noted an
increase in the levels of the major reducible bifunctional collagen
crosslinks, dehydrodihydroxylysinonorleucine (DHLNL), and hy-
droxylysinonorleucine (HLNL) in the breast tumors, reflecting
elevated crosslinked collagen (Figure 1G). We further detected
increased amounts of the amine oxidase crosslinking enzyme,
LOX, in the stromal cells of the premalignantMin foci and invasive
tumors and in the invading transformed epithelium (Figure 1H).
These data establish an association between collagen cross-
linking, LOX expression, ECM stiffness, and tissue fibrosis in
Neu-induced breast tumorigenesis.
LOX-Mediated Collagen Crosslinking and Tissue
Stiffening Promote Focal Adhesions and Tumor
Progression In Vivo
We next asked whether LOX-mediated collagen crosslinking
could stiffen the breast and promote invasion of a premalignant
lesion. We used Ha-ras human MCF10AT MECs which upon
injection into mice develop into premalignant tissues (Hu et al.,
2008). We conditioned inguinal mammary fat pads of NOD/
SCID mice, surgically cleared of their epithelium, with control
fibroblasts or those expressing elevated LOX (Figures 2A, S2,
and S3). Rheological measurement revealed that the mammary
glands conditioned with LOX expressing fibroblasts were stiffer
(Figure 2B), picrosirius red staining showed that they had more
fibrillar collagen (Figures 2C and 2D), and SHG imaging revealed
that they had more linearized collagen (Figures 2C and 2E).
Consistent with ECMstiffening, resident fibroblasts in the epithe-
lial-cleared LOX-treated glands showed more FAKpY397 and
p130Cas immunostaining, indicative of increased focal adhesions
and mechanosignaling in the stromal cells (Figure 2C, bottom).
LOX preconditioning and stiffening of the mammary gland
promoted the growth and invasion of Ha-ras premalignantFigure 1. ECM Stiffening, Collagen Crosslinking, and Tissue Fibrosis Accompany Breast Transformation
(A) Elastic modulus of mammary glands from FVB MMTV-Neu mice at different stages of tumor progression measured by unconfined compression.
(B) Shear rheology of tissues described in (A).
(C) Top row: confocal images of tissues in (A) stained for cytokeratin 14 (red) and DAPI (nuclei; blue). Middle and bottom rows: photomicrographs of tissues in (A)
stained with picrosirius red and hematoxylin, viewed under parallel (middle) and orthogonal polarizing filters (bottom).
(D) Quantification of images in (C).
(E) SHG images of tissues described in (A).
(F) Quantification of images in (E).
(G) Scatter plot of collagen crosslinks.
(H) Confocal images of tissues described in (A) stained for lysyl oxidase (LOX, red) and DAPI (nuclei, blue). Images are at 403. Scale bars represent 25–50 mm.
Values in (A), (B), and (D) are shown as mean ± standard error of the mean (SEM) of four to six glands/condition. *p% 0.05, **p% 0.01, ***p% 0.001.Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 893
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Figure 2. Collagen Remodeling and Tissue Stiffening Promote Focal Adhesions and Tumor Invasion
(A) Experimental design.
(B) Scatter plot of breast rheology after LOX (FB.LOX) or control (FB.ctrl) fibroblast conditioning.
(C) Top two panels: photomicrographs of tissues described in (B) stained with picrosirius red and hematoxylin viewed under parallel and orthogonal polarizing
filters. Scale bars represent 50 mm. Third panel: SHG images of tissues from fibroblast-conditionedmammary glands. The scale bar represents 25 mm. Fourth and
fifth panels: confocal images of fibroblasts residing within fibroblast-conditioned mammary glands stained for active FAK (FAKpY397, red, fourth panel), p130Cas
(red, fifth panel), and DAPI (nuclei, blue). The scale bar represents 50 mm.
(D) Scatter plot of fibrillar collagen in tissue shown in (C).
(E) Scatter plot of collagen linearity measured by curvature ratio from SHG images shown in (C).894 Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc.
mammary organoids injected into these tissues as revealed by
a significant increase in lesion size and tumors that lacked
margins (Figures 2F–2H). MECs in the LOX preconditioned
glands also had more focal adhesions, as revealed by elevated
FAKpY397 (Figure 2H) and p130Cas (data not shown). To rule out
any direct effect of LOX activity on MEC behavior, we also
treated a cohort of animals in parallel (i.e., at time of MEC injec-
tion) with b-aminopropionitrile (BAPN), a natural and irreversible
inhibitor of lysyl oxidase activity (Kagan and Li, 2003). Because
BAPN treatment had no effect on tumor growth, invasion, and
focal adhesions (Figures S4–S6), we concluded that it was LOX
preconditioning of the stroma and ECM stiffness that promoted
mammary tumor progression, and not any direct effect of LOX
on the mammary epithelium. These findings demonstrate how
ECM crosslinking and stiffening can induce focal adhesions
and promote the growth and invasion of an oncogene-initiated
mammary epithelium in vivo.
Inhibition of LOX-Mediated Collagen Crosslinking
Decreases Fibrosis and Reduces Focal Adhesions to
Inhibit Breast Tumor Progression In Vivo
We next asked whether reduction of LOX-dependent collagen
crosslinking could temper tissue fibrosis and decrease focal
adhesions, and whether this would inhibit breast tumor progres-
sion. We inhibited LOX activity using the cell-soluble BAPN
(Lucero and Kagan, 2006) or a LOX-specific function-blocking
polyclonal antibody that only inhibits extracellular LOX activity
(Erler et al., 2006) and assayed collagen crosslinking, tissue
fibrosis, focal adhesions, and breast tumor development.
Inhibition of LOX activity was initiated in five month old parous
animals, when LOX levels were already increased in the stromal
cells but were non-detectable in the mammary epithelium
(Figure 1H). Treatment was continued for 1 month, after which
the animals were allowed to recover for another month and
then sacrificed (Figure 3A). At the time of sacrifice, the non-
treated MMTV-Neu mice had high levels of active LOX in the
serum, whereas BAPN or LOX-inhibitory polyclonal antibody-
treated animals had reduced levels (Figure 3B). Mice with
reduced LOX activity showed significant decreases in LOX-
mediated collagen crosslinks, both reducible (DHLNL and
HLNL) and nonreducible (pyridinoline) (Figures 3C and 3D), and
the collagen fibrils adjacent to the epithelial lesions were less
linear (Figures 3E and 3F). Consistent with the possibility that
inhibition of collagen crosslinking prevented tissue fibrosis, LOX
inhibition reduced fibrillar collagen (Figures 3G and 3H) and
had less focal adhesions, as indicated by negligible FAKpY397
(Figure 3I).
Inhibition of LOX activity also increased tumor latency
(Figure 4A) and decreased tumor incidence (Figure 4B), despite
ErbB2 activity (Figure 4C). Moreover, the palpable lesions
formed in the LOX-inhibited animals were smaller (Figure 4D)and less proliferative (Figure 4E). LOX-inhibited mammary
glands also stained positively for cytokeratin 14 along the basal
periphery of the ducts, implying retention of their myoepithelium
(Figures 4H and 4I). Hematoxylin and eosin (H&E) sections
revealed that a significantly greater proportion of the lesions in
the LOX-inhibited animals were hyperplastic or premalignant
(hyperplastic alveolar nodules [HANs] ormammary intraepithelial
neoplasias [MINs]) and the tumors that did develop were
mostly low grade as opposed to the high grade carcinomas
typically observed in the untreated Neu mice (Figures 4G and
4F). These results show how inhibition of LOX activity reduces
collagen crosslinking, tempers tissue fibrosis, decreases focal
adhesions, and impedes tumor progression to reduce breast
tumor incidence.
Collagen Crosslinking and ECM Stiffening Promote
Focal Adhesions and Drive Invasion of Oncogenically
Initiated Mammary Tissues in Culture
We next assessed the effect of nonspecific induction of collagen
crosslinking and stiffening on MEC invasion in the absence
of fibroblasts, immune cells, and other stromal and systemic
cellular and soluble factors (Figure 5A, experimental design).
We explored the effect of nonspecific collagen crosslinking and
stiffening on tumor invasion by adding ribose to the media of
nonmalignant, MCF10A acini embedded in a 3D soft collagen I/
reconstituted basement membrane gel (Col/rBM gel).
To determine whether MEC invasion required oncogenic
signaling, we utilized MCF10As expressing an ErbB2 chimera
(ErbB2.chim; called HER-2; the human homolog of Neu) con-
sisting of the extracellular and transmembrane domains of
low-affinity nerve growth factor receptor (p75NGFR), and the
cytoplasmic kinase domain of ErbB2 linked to the synthetic
ligand-binding domain from the FK506-binding protein (FKBP).
In these MECs, addition of the synthetic bivalent FKBP ligand,
AP1510, drives homodimerization of ErbB2, activation of the
kinase domain, and initiation of ErbB2 signaling (Muthuswamy
et al., 2001). Chimeric ErbB2 signaling drives proliferation and
luminal filling but fails to induce MEC invasion in rBM (Figure 5E).
To study effects of homo- (ErbB2/ErbB2) and heterodimer
(ErbB1/ErbB2) formation, we also engineered MECs in which
the wild-type ErbB2 could be overexpressed through addition
of doxycycline (ErbB2.TetOn; Figures S7 and S8).
In the absence of ErbB2 activity, MECs in collagen/rBM gels
assembled acini, as illustrated by basally oriented b4 integrin
and cell-cell localized beta catenin (Figure 5E). Glycation-medi-
ated crosslinking stiffened the collagen (Figure 5B), increased
colony size (Figure 5C), and disrupted tissue organization, as
revealed by diffusely localized beta catenin and the appearance
of random cells within the lumens (Figure 5E). MECs within the
ribose crosslinked collagen gels also had elevated levels and co-
localized b1 integrin and FAKpY397, indicative of tension-induced(F) Rheology of mammary glands with injected Ha-ras MCF10AT MECs.
(G) Lesion burden for mouse cohorts.
(H) Top: photographs of mammary glands 3 weeks after injection with Ha-ras MCF10AT organoids. Middle: H&E-stained tissue of MECs from lesions shown in
(H). Bottom: confocal images of MECs in tissue shown in (H) stained for b1 integrin (red), active FAK (FAKpY397, green) and DAPI (nuclei, blue, inset). Scale bars
represent 50 mm.
Values in (E) and (G) are mean ± SEM of several glands. *p% 0.05.Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 895
ATreat mice with
BAPN/LOX-Ab
End
Treatment
Sacrifice
all mice
Birth 5mo 6mo 7mo
B
Control +BAPN +LOX-Ab
0
50
100
L
O
X
A
c
tiv
ity
(S
p
.
F
lu
o
r
[x
1
0
3
])
E
S
H
G
25 m
Control LOX-Inhib
Control LOX-Inhib
1.0
1.2
1.4
1.6
1.8
C
u
rv
a
tu
re
R
a
tio
C
F
H
Control LOX-Inhib
0
10
20
30
40
***
T
h
re
s
h
o
ld
e
d
A
re
a
(%
)
G
50 mP
S
 R
e
d
(P
a
ra
lle
l)
P
S
 R
e
d
(O
rt
h
o
g
o
n
a
l)
Control LOX-Inhib
I
Control
50 m
LOX-Inhib
F
A
K
D
A
P
IpY
3
9
7
Control LOX-Inhib Control LOX-Inhib
0
1
2
3
** *
R
e
d
.
C
ro
s
s
lin
k
s
(m
o
l/m
o
lc
o
lla
g
e
n
)
DHLNL HLNL
Control LOX-Inhib
0.00
0.25
0.50
0.75
***
N
o
n
re
d
.
C
ro
s
s
lin
k
s
(m
o
l/m
o
lc
o
lla
g
e
n
)
D
Pyridinoline
Figure 3. Inhibition of Collagen Crosslinking Tempers Tissue Fibrosis and Reduces Focal Adhesions
(A) Experimental design.
(B) LOX enzymatic activity in serum of untreated (Control) compared to BAPN (+BAPN) or LOX-inhibitory antibody-treated (+LOX-Ab) Neumice. Values are shown
as mean ± SEM.
(C) Scatter plots of reducible collagen crosslinks in LOX-inhibited (LOX-Inhib) and untreated (Control) Neu breasts.
(D) Scatter plots of pyridinoline in LOX-inhibited (LOX-Inhib) and untreated (Control) Neu breasts.
(E) SHG images of mammary glands from BAPN-treated animals as described above. The scale bar represents 25 mm.
(F) Collagen curvature in SHG images from (D) (Supplemental Experimental Procedures). Data are mean ± SEM of three to five regions/four glands/condition.
(G) Photomicrographs of sections from control and BAPN-treated (LOX-Inhib) Neu mammary glands stained with picrosirius red and hematoxylin viewed under
parallel or orthogonal polarizing filters. The scale bar represents 50 mm.
(H) Fibrillar collagen in control and LOX-inhibited glands from images shown in (F). Data are mean ± SEM of four to six images/four to eight glands/condition.
(I)Confocal imagesof sections fromcontrolandBAPN-treatedNeuglandsstained foractiveFAK(FAKpY397, red)andDAPI (nuclei,blue).Thescalebar represents50mm.
*p% 0.05, **p% 0.01, ***p% 0.001.896 Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc.
focal adhesions (Figure 5D). Nevertheless, in the absence of
ErbB2 activity, ECM stiffening did not drive MEC invasion
(Figures 5E and 5F).
Addition of either AP1510 (1 mM) or doxycycline (0.2 mg/mL) to
the mammary acini, induced and activated (ErbB2.TetOn) or
directly activated ErbB2 (ErbB2.chim) (Figure S9), promoted
cell growth (data not shown), drove luminal filling, and destabi-
lized cell-cell junctions, as revealed by diffusely localized beta
catenin (Figure 5E). Sustained ErbB2 activation did not drive
MEC invasion, as indicated by colony integrity and the retention
of basally localized b4 integrin (Muthuswamy et al., 2001)
(Figures 5E and 5F). Yet, when ErbB2 was activated in colonies
in the crosslinked, stiffened gels, colony architecture disinte-
grated, as revealed by the absence of detectable beta catenin
and disorganized b4 integrin staining, and MECs invaded into
the gels (Figure 5E, white arrows; quantified in Figure 5F). SHG
imaging revealed that individually, ErbB2 activation and ECM
stiffening were accompanied by the appearance of prominent
collagen bundles surrounding the colonies and showed that
MECs with activated ErbB2 invaded on fibrils that extended
perpendicularly into the crosslinked, stiffened gels (Figurs 5E,
white arrows highlight an invasive MEC, yellow arrows indicate
collagen reorganization; Figure S9). These findings show how
collagen crosslinking and ECM stiffening, per se, cooperate
with oncogenes such as ErbB2 to promote the invasive behavior
of a mammary epithelium.
Interestingly, confocal imaging revealed elevated p130Cas and
FAKpY397 staining that colocalized with b1 integrin (colocalization
analysis of FAKpY397 and b1 integrin; Pearson’s r = 0.78; p130Cas
and b1 integrin, Pearson’s r = 0.89) in the stiffer breast tissue of
the Neu mice (Figure 6A; see insert) and reduced levels of
FAKpY397 after LOX inhibition (Figure 3H). Moreover, inhibition
of b1 integrin activity, with the function blocking antibody AIIB2,
or reduction of integrin signaling by expression of an inducible
FRNK (FRNK.TetOn; Figure S10) prevented the force-mediated
invasion of the ErbB2 activated mammary organoids (Figures 5G
and 5H). These findings showhowECMcrosslinking and stiffness
cooperate with an oncogene to promote breast cell invasion and
implicate integrin signaling in force-dependent tumorprogression.
Integrin Clustering Promotes Focal Adhesions to Drive
Invasion of a Ha-ras Mammary Epithelium In Vitro and
In Vivo
To determine whether integrin signaling would be sufficient to
induce breast tumor invasion, we expressed a series of integrin
constructs in nonmalignant MCF10A and Ha-ras premalignant
MCF10AT MECs and assayed for invasive behavior in rBM and
in vivo (Figure 6B).
Expression of the V737N integrin, which recapitulates tension-
dependent integrin clustering, promoted focal adhesions, indi-
cated by elevated FAKpY397 (Figure 6C), and disrupted the
integrity of mammary colonies in rBM, revealed by luminal filling
and altered b4 integrin localization (Figure 6C, top). In contrast,
expression of neither a wild-type (Figure 6C) nor a constitutively
active b1 integrin (not shown; Paszek et al. [2005]) induced focal
adhesions and disrupted mammary tissue architecture. More-
over, while the V737N b1 integrin mutant failed to promote inva-
sion of the MCF10A MECs (Figure 6C), the V737N integrininduced the invasion of the Ha-ras premalignant MCF10AT colo-
nies in rBM (Figures 6D and 6E). Upon injection into nude mice,
the V737N integrin not only promoted focal adhesions and
increased lesion size (Figure 6F), but also induced the invasive
behavior of the Ha-ras MCF10AT organoids, as revealed by
the loss of epithelial lesion margins and increased FAKpY397
(see arrows in Figure 6G). These findings implicate tension-
dependent integrin clustering and focal adhesions in breast
tumor invasion. However, because integrin clustering could
only promote invasion in Ha-ras premalignant MECs, they also
illustrate how integrin-mediated mechanotransduction cooper-
ates with oncogenic signaling to drive malignancy.
Collagen Crosslinking and Tissue Stiffness Promote
Integrin Clustering and Enhance PI3K Signaling to
Regulate Invasion of a Premalignant Mammary
Epithelium In Vitro and Tumor Progression In Vivo
Integrins activate PI3K, and PI3K promotes invasion in culture
and tumor progression in vivo (Webster et al., 1998). Therefore,
we explored the relationship between focal adhesions and
PI3K signaling in tension-dependent breast tumor invasion. We
found Akt signaling, an established target of PI3K, to be elevated
in the premalignant and malignant, rigid mammary tissue
(Figure 7A) and in the mammary colonies in the ribose-stiffened
collagen gels (Figure 7B).
We examined the effect of ECM rigidity on PI3K activity in
MECs plated on rBM-functionalized polyacrylamide gels (rBM
PA gel) with elastic moduli of 140–400 (soft) and R5000–
10,000 (stiff) Pascals. These two extremes represent the ECM
stiffness of healthy versus transformed breast tissue. Although
substrate stiffness did not increase the levels of AktpS473 in unsti-
mulated MECs, ECM stiffness potentiated the magnitude of
EGF-activated AktpS473 (Figure 7C) and increased ErbB2-acti-
vated AktpS473 (Figure 7D). MECs on soft gels that expressed
the b1 integrin cluster mutant, but not the wild-type b1 integrin,
also showed a significant increase in AktpS473 activity after
EGF stimulation. These results suggest that integrin mechano-
transduction potentiates growth factor dependent PI3 kinase
signaling (Figures 6B, 6C, and 7E).
Pharmacological inhibition of PI3K activity with LY294002
restored thecolonyarchitectureofErbB2-activatedMECs in ribose
crosslinked collagen gels toward that of a noninvasive, polarized,
cohesive colony (Figures 7F and 7G). Inhibition of PI3K activity
reduced colony size, and immunostaining revealed that colonies
treated with LY294002 retained b catenin at cell-cell junctions
and had basally localized b4 integrin (Figure 7F). The epithelium
from the LOX-inhibited Neu mice also had lower PI3K signaling,
asrevealedbyfainteractiveAkt/PI3Ksubstratestaining (Figure7H).
These data are consistent with a role for integrin mechanotrans-
duction in PI3K-mediated breast tumor invasion. The findings
suggest thatECMstiffness, as inducedbyelevatedcollagencross-
linking could promote breast malignancy by enhancing integrin-
GFR crosstalk (Figure 7I) (Miranti and Brugge, 2002).
DISCUSSION
Our findings identify collagen crosslinking as a critical regulator
of desmoplasia and imply that the level and nature of ECMCell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 897
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Figure 4. Inhibition of Crosslinking Reduces Tissue Fibrosis and Tumor Incidence and Enhances Tumor Latency
(A) Tumor latency.
(B) Tumor incidence without (Control) or with (LOX-Inhib) LOX inhibition.
(C) Confocal images of activate ErbB2 (ErbB2pY1248, red) in tissues from FVB nontransgenic littermates, Neu (MMTV-Neu) and LOX-inhibited mice (MMTV-
Neu +LOX-Inhib). The scale bar represents 50 mm.
(D) Tumor size in control and LOX-inhibited mice.
(E) Confocal images of sections from LOX-inhibited and control glands stained for PCNA (red) and DAPI (nuclei, blue). The scale bar represents 50 mm.
(F) Grading of tumor lesions from mammary glands of control (n = 14) and BAPN-treated (LOX-Inhib, n = 13) animals.
(G) H&E-stained tissue showing typical normal glandular structure, hyperplastic alveolar nodules (HANs), and mammary intraepithelial neoplasias (MINs) prema-
lignant lesions and grades I, II, and III ductal tumors.898 Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc.
crosslinks in a tissue could impact cancer risk and alter tumor
behavior. The observations are consistent with links between
ECM crosslinking and tissue stiffening in tissue fibrosis and
could explain the increased risk to malignancy associated with
these conditions (Colpaert et al., 2003). They might also explain
why women with mammographically dense breasts have an
increased relative risk of developing cancer (Martin and Boyd,
2008). Because aged tissues are stiffer and contain high levels
of aberrant collagen crosslinks, the data offer a new paradigm
for understanding why tumor incidence increases so dramati-
cally with aging (Szauter et al., 2005).
Tissue fibrosis influences tumor progression by regulating
soluble factors that induce inflammation and angiogenesis and
stimulate cell growth and invasion (Bierie et al., 2009; Coussens
et al., 1999).We showed thatmodification of the state of collagen
crosslinking and ECM stiffness, two physical parameters of the
tissue microenvironment, modulated the invasive behavior of
an oncogene pre transformed mammary epithelium, even in
the absence of cellular and soluble tissue and systemic factors.
The findings imply that tissue fibrosis could regulate cancer
behavior by influencing the biophysical properties of the micro-
environment to alter force at the cell and/or tissue level. Impor-
tantly, we noted that focal adhesions were elevated in the
stiffened breast tumors and organoid cultures, that forcing focal
adhesions promoted MEC invasion, and that inhibiting focal
adhesion signaling or tempering tissue stiffening reduced focal
adhesions and tumor invasion. These observations are consis-
tent with the notion that force regulates the invasive behavior
of tumors by modulating integrin activity and focal adhesion
assembly and signaling (Paszek et al., 2005). The findings
thereby provide an explanation for why pYFAK and p130Cas
are so often increased in breast tumors (Cabodi et al., 2006;
Madan et al., 2006), even when integrin expression is frequently
decreased (Koukoulis et al., 1993; Zutter et al., 1998). Indeed, the
observations suggest that enhanced integrin signaling rather
than just an increase in integrin expression is more critical for
tumor progression.
Our data show how modulating the activity of one class of
ECM crosslinking enzymes, the LOXs, can directly modify tumor
progression by regulating collagen crosslinking and stiffness.
The results are consistent with data indicating that LOX enzymes
are elevated in many cancers (Erler and Weaver, 2009) and that
LOX is induced by hypoxia inducible factor (HIF-1) and TGFb,
two key regulators of tumor behavior (Postovit et al., 2008).
Indeed, cellular LOX promotes breast cell migration and invasion
and enhances tumor proliferation and survival (Kirschmann
et al., 2002). Hypoxia-induced LOX modulates tumor metastasis
by regulating integrin function (Erler and Giaccia, 2006) by
facilitating tumor extravasation (Bondareva et al., 2009) or by
conditioning the metastatic niche (Erler et al., 2009). Our work
indicates that LOX can promote tumor progression and MEC
invasion by increasing fibrillar collagen and ECM stiffness. These
observations are consistent with the major function of LOX in
tissues as a key enzyme for collagen and elastin crosslinkingthat enhances tensile strength (Szauter et al., 2005). Consis-
tently, by inhibiting LOX activity early, when levels were high in
the stroma, we prevented ECM remodeling and stiffening and
reduced tumor progression in the MMTV-Neu mice. Because
a LOX-specific inhibitory polyclonal that cannot inhibit intracel-
lular LOX also prevented fibrosis and tumor progression, our
results suggest that LOX-mediated collagen crosslinking likely
regulates breast tumor progression by modifying the tumor
microenvironment rather than by directly changing cell behavior.
We observed that LOX inhibition reduced focal adhesions and
PI3K signaling indicating that LOX modulates breast tumor
progression by stiffening the ECM to drive focal adhesions
assembly and enhance GFR-dependent PI3K signaling. Consis-
tently, we showed that ribose-mediated collagen crosslinking,
which induces nonspecific collagen glycation, also stiffened the
ECM and enhanced focal adhesions and PI3K signaling to
promote ErbB2-dependent breast tumor invasion. We noted that
MEC invasion could be abrogated by inhibition of integrin and
FAK activity, thereby illustrating the importance of ECM crosslink-
ing and stiffness in tumor progression. This idea is consistent with
our recent findings that LOX conditioning of the lung ECM
promotes breast tumor metastasis (Erler et al., 2009) and data
showing that fibrotic breast tumors have the poorest prognosis
and highest rate of recurrence (Hasebe et al., 1997). Indeed, our
findings underscore the notion that ECM crosslinking and stiff-
ness, per se, is a key regulator of tumor progression. They imply
that other ECM crosslinkers/modulators implicated in tissue
fibrosis such as tissue transglutaminase, lysyl hydroxylase or
some of the proteoglycans or even non-specific metabolic glyca-
tionendproducts (AGEs)might alsosimilarlypromotemalignancy.
LOX has been proposed to be a tumor suppressor (Payne
et al., 2007) possibly by directly inhibiting ECM adhesions and
integrin signaling (Zhao et al., 2008). LOX-mediated ECM stiff-
ening could also impede cell invasion in the absence of MMP
activity (Zaman et al., 2006) reminiscent of highly crosslinked,
stiff fibrotic tissues and scars that often never progress to malig-
nancy. We noted that neither ECM stiffness nor forced integrin
clustering induced mammary tissue invasion in the absence of
oncogenic signaling. This suggests that other factors that modu-
late integrins and/or ECM remodeling or cellular tension likely
cooperate with ECM crosslinking and force to promote tumor
invasion (Katz et al., 2007; Wolf et al., 2007). Instead, ECM stiff-
ness appears to operate as a signaling rheostat potentiating
oncogenic cues to promote tumor invasion.
Cancer progression is accompanied by MMP-dependent
ECM remodeling.MultipleMMPs are overexpressed in the tumor
stroma, and some MMPs are upregulated in transformed
epithelia (Jodele et al., 2006; Page-McCaw et al., 2007). Elevated
expression of specific MMPs induced desmoplasia and malig-
nant transformation (Sternlicht et al., 1999) and genetic ablation
of MMPs or pharmaceutical inhibition of MMP activity reduced
breast metastasis (Martin et al., 2008). These data argue that
MMPs are critical for malignancy. Nevertheless, clinical trials
with MMPs failed, suggesting that the role of MMPs in cancer(H) Confocal images of breast tissue stained for cytokeratin 14 (red) and DAPI (nuclei, blue) in control and LOX-inhibited tissue. The scale bar represents 50 mm.
(I) Quantification of cytokeratin 14 positive glands in (H) detected in breast from control and LOX-inhibited animals.
Values in (A), (B), (D), (F), and (I) are shown as mean ± SEM of four to six measurements/four to 12 tissue sections/group. *p% 0.05, **p% 0.01, ***p% 0.001.Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 899
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is more complicated (Coussens et al., 2002). Indeed, MMPs
collaborate with crosslinking enzymes such as LOX to facilitate
collagen maturation, and MMPs and LOX regulate the expres-
sion and activity of soluble factors such as transforming growth
factor beta (TGFb) that regulate tumor cell behavior (Atsawasu-
wan et al., 2008; Csiszar, 2001; Decitre et al., 1998; Szauter
et al., 2005). TGFb in turn regulates the expression of many
ECM proteins and modifying enzymes including LOXs, and
TGFb increases levels of factors that evoke inflammation, induce
fibrosis and promote metastasis (Bierie and Moses, 2006; Oleg-
gini et al., 2007). Indeed, force itself modulates TGFb activation
and compression alters growth factor signaling (Tschumperlin
et al., 2004; Wipff et al., 2007). These findings underscore the
dynamic and reciprocal relationship between ECM deposition,
processing, degradation, and force. They suggest that cancer
is best viewed as a dynamic, phenotypically plastic, and highly
coordinated tissue remodeling process that is tightly regulated
by biochemical and mechanical cues. Accordingly, not only will
we need to clarify the role of ECM cleavage in tumors but we
will also be obliged to understand how ECM remodeling is inte-
grated within the context of its deposition, posttranslational
modifications, and topological rearrangement and to take into
consideration the effect of mechanical force as a key regulator
of malignancy.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Antibodies were as follows: b4 integrin (3E1); b1 integrin (AIIB2, Chemicon);
FAK (77), YES (1), b1 integrin (18), E-Cadherin (610405, BD Transduction);
laminin-5 (BM165, MP Marinkovich); b actin (AC-15, Sigma); ErbB2 (3B5,
Calbiochem); polyclonal b catenin (Sigma); FAKpY397 (BioSource); Phospho-
(Ser/Thr) Akt Substrates and AktpS473 (Cell Signaling); Akt (BD PharMingen);
p130Cas, ErbB2pY1248 (Abcam); cytokeratin 14 (Covance); LOX (A. Giaccia,
Stanford University); LOX polyclonal activity inhibitory antibody (OpenBiosys-
tems); and secondary AlexaFluor goat anti-mouse, anti-rabbit, and anti-rat
(488 and 555 conjugates), AlexaFluor phalloidin (488 conjugate, Invitrogen);
donkey anti-mouse and anti-rabbit (Cy2 and Cy3 conjugates, Jackson Immu-
noResearch); and sheep anti-mouse and anti-rabbit HRP-linked (Amersham).
Reagents included LY294002 (50 mm in DMSO, Calbiochem).
Cell Manipulations
MEC and fibroblast cell lines were cultured as described (Paszek et al., 2005).
Collagen crosslinking was induced by addition of 15 mM ribose to the culture
medium (Girton et al., 1999). rBM-conjugated PA gels with calibrated stiffness
were prepared as described (Johnson et al., 2007).Vector Constructs and Gene Expression
Full-length human ErbB2 (K. Ignatoski) was cloned into the pRet puro Tet IRES
EGFP tetracycline-inducible vector. The b1 integrin wild-type, b1 integrin
glycan wedge constitutively active, and b1 integrin clustering mutant V737N
constructs and the preparation of virus and cell infection and selection
have been described (Paszek et al., 2005). Four myc tags were added to the
C terminus of full-length LOX and cloned into the pLV puro TetO7mCMV tetra-
cycline-inducible lentiviral vector and expressed biscistronically with eGFP.
Elastic Modulus Measurements
Mammary glands and gels were assayed for materials properties by uncon-
fined compression and rheometrical analysis (Paszek et al., 2005) (Supple-
mental Experimental Procedures).
Mice and Treatments
FVB-TgN MMTV-Neu, NOD/SCID, and BalbC nu/nu mice (Jackson Labora-
tory) were maintained in accordance with University of Pennsylvania and
University of California Institutional Animal Care and Use Committee guide-
lines. For LOX-inhibition studies, animals were treated with BAPN (3 mg/kg;
Spectrum) in the drinking water (four to eight mice/group, four studies) or
a LOX function-blocking polyclonal antibody (3 mg/kg; OpenBiosystems,
D8746) injected intraperitoneally twice per week (three to four mice/group,
one study). Mice were sacrificed at 7–7.5 months of age, at which time tail
vein blood was collected. Lesions were detected by palpation (3 mm diam-
eter), and tumor volume was assessed with calipers. At sacrifice mammary
glands were excised, imaged, andmechanically tested or snap frozen or para-
formaldehyde fixed.
Tumor Grading
Tumor grading was performed blinded on H&E-stained sections from
untreated (n = 14) or BAPN-treated (n = 13) #2–3 mammary glands. Premalig-
nant lesions were defined as HAN- or MIN-like foci. Grade I lesions were well
defined as homogenous carcinomas, grade II contained areas with strong
necrosis, stromal reaction and/or red blood cells outside of tumor blood
vessels, and grade III also contained necrosis and nuclear pleiomorphy. Adja-
cent tissue was defined as mammary tissue surrounding a tumor that was cut
away from the tumor prior to subsequent analysis. A small set of anti-LOX-
treated mice (n = 4) was compared with their controls (n = 3), and showed
they the same tendency to less progressed lesions as was observed in the
BAPN-treated animals.
Xenograft Manipulations
NOD/SCID mice (n = 24) were used for mammary fat pad transplantation
studies (Kuperwasser et al., 2004). In brief, the rudimentary inguinal epithelium
was removed from 3-week-old anesthetized female mice and 53 105 NIH 3T3
WT or LOX-expressing fibroblasts (2.53 105 were treated with 4Gy irradiation
24 hr prior to injection) were injected into the left and right mammary glands.
Two weeks after fibroblast injection, 1 3 106 DCIS.com MCF10AT MEC 4-
day-old rBM-generated, proliferating organoids (16–20 cells/organoid) were
suspended in Dulbecco’s modified PBS and injected into the preconditionedFigure 5. Collagen Crosslinking and ECM Stiffening Promote Focal Adhesions and Invasion of ErbB2 Mammary Colonies
(A) Experimental design.
(B) Elastic modulus of ribose crosslinked (+Ribose) and untreated (Control) collagen gels.
(C) Cross-sectional area of MEC colonies in +ribose and control gels.
(D) Confocal images ofMCF10A colonies stained for b1 integrin (green), activate FAK (FAKpY397, red), and DAPI (nuclei, blue) in control and +ribose gels. The scale
bar represents 20 mm.
(E) Top panels: confocal images of MEC colonies expressing the ErbB2 chimera stained for b catenin (green), b4 integrin (red), and DAPI (nuclei, blue) in control
or +ribose gels with (+ErbB2) or without ErbB2 activity. Bottom panels: SHG images of collagen fibrils and confocal images of eGFP expressing MEC colonies
as described above. Scale bars represent 20 mm. Yellow arrows identify collagen bundles surrounding the colony periphery, and white arrows indicate an in-
vading MEC.
(F) Percent colony invasion shown in (E).
(G) Phase-contrast images of MEC colonies expressing the ErbB2 chimera in control or +ribose gels, with active ErbB2 (+ErbB2), coexpressing a doxycycline-
inducible FRNK (right panel) or treated with b1 integrin function-blocking antibody (+b1 block).
(H) Percent colony invasion shown in (G).
Values in (B), (C), (F), and (H) are shown as mean ± SEM from three to five experiments and/or 50–100 colonies in three experiments. **p% 0.01, ***p% 0.001.Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc. 901
AC
E F
G
D
B
Figure 6. b1 Integrin Clustering Promotes Focal Adhesions andDrives Invasion of a PremalignantMammary Epithelium inCulture and In Vivo
(A) Combined and split (inserts) confocal images of tissue sections from MMTV-Neu breast stained for DAPI (nuclei, blue) and p130Cas (red, top), or b1 integrin
(green, bottom) and activate FAK (FAKpY397, red). The scale bar represents 20 mm. (Colocalization analysis of the malignant tumors: FAKpY397 and b1 integrin,
Pearson’s r = 0.78; p130Cas and b1 integrin, Pearson’s r = 0.89.)
(B) b1 integrin constructs used for the studies shown in (C)–(G).
(C) Confocal images ofMCF10AMEC rBMcolonies expressing the b1 integrin wild-type [b1(WT)] or clusteringmutant [b1(V737N)] stained for b4 integrin (red, top),
active FAK (FAKpY397, red, bottom) and DAPI (nuclei, blue).902 Cell 139, 891–906, November 25, 2009 ª2009 Elsevier Inc.
fat pads. All mice were sacrificed at 8 weeks of age (3 weeks after MEC injec-
tion and 5 weeks after fibroblast injection), lesion volume was assessed by
caliper measurement, photographed in situ, and dissected gland fragments
were imaged and mechanically tested or snap frozen, or fixed and paraffin
embedded.
Subcutaneous Studies
Proliferating rBM-generated organoids (16–20 cells/organoid) from each
experimental condition were injected subcutaneously into the rear flanks of
BalbC nu/nu mice (six to eight mice/group; 5–10 3 106), tumor formation
was monitored for 3 weeks, and samples were assessed as above at study
termination.
Collagen Crosslinking
Mammary gland collagen was reduced with standardized NaB3H4, hydrolyzed
with 6N HCl, and subjected to amino acid and collagen crosslink analyses as
described (Yamauchi and Shiiba, 2008) (Supplemental Experimental Proce-
dures). The reducible crosslinks, dehydro-dihydroxylysinonorleucine (deH-
DHLNL) and deH-hydroxylysinonorleucine (deH-HLNL), their ketoamines,
were identified as their reduced forms, i.e., DHLNL and HLNL. The crosslinks
analyzed (reducible and nonreducible) were quantified as moles/mole of
collagen based on the hydroxyproline value of 300 residues per collagenmole-
cule. LOX activity was measured in cell supernatant and plasma as described
(Erler et al., 2006).
Immunostaining and Imaging
Immunofluorescence and imaging of 3D cultures and tissueswas as described
(Paszek et al., 2005). Picrosirius red analysis was achieved through the use of
paraffin sections of mammary glands stained with 0.1% picrosirius red (Direct
Red80, Sigma) and counterstainedwithWeigert’s hematoxylin to reveal fibrillar
collagen. Sections were serially imaged with an Olympus IX81 fluorescence
microscope fitted with an analyzer (U-ANT) and polarizer (U-POT, Olympus)
oriented parallel and orthogonal to each other and quantified with minimal
thresholding. Two-photon second harmonics imaging was performed on
aPrairie TechnologyUltimaSystemattached to anOlympusBX-51with awater
immersion objective, and sampleswere quantified by calculation of the linearity
of multiple collagen fibrils (see the Supplemental Data for further details).
Immunoblot Analysis
Cells were lysed in RIPA or Laemmli buffer and assayed by immunoblotting
(Johnson et al., 2007).
Statistics
Statistical analysis was performed with GraphPad Prism with an unpaired
student’s t test, two-way ANOVA, or Fisher’s exact test.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and 11
figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(09)01353-1.
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